期刊文献+

他汀类药物与动脉粥样硬化性心血管疾病一级预防:我们所处何处?该有何为? 被引量:7

原文传递
导出
摘要 血浆胆固醇尤其是LDL—C水平升高是动脉粥样硬化性心血管疾病(ASCVD)致病性危险因素。大量研究证实,降低LDL-C对于动脉粥样硬化性心血管事件的预防起到关键的作用。他汀类药物是目前临床调脂药物中降低LDL-C作用最强、安全性和耐受性最好的药物,近30年来的一系列大规模随机对照研究均表明,他汀类药物治疗将LDL-C水平显著降低,可使ASCVD再发和初发事件大幅度降低。
作者 李勇
出处 《中华内科杂志》 CAS CSCD 北大核心 2016年第4期260-263,共4页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献33

  • 1BaigentC, KeechA, KearneyPM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins[J]. Lancet, 2005, 366(9493):1267-1278. 被引量:1
  • 2KearneyPM, BlackwellL, CollinsR, et al. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis[J]. Lancet, 2008, 371(9607):117-125. 被引量:1
  • 3HoogeveenRC, GaubatzJW, SunW, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study[J]. Arterioscler Thromb Vasc Biol, 2014, 34(5):1069-1077. 被引量:1
  • 4SchmidtSA, Heide-J?rgensenU, ManthripragadaAD, et al. Prevalence and characteristics of patients with low levels of low-density lipoprotein cholesterol in northern Denmark: a descriptive study[J]. Clin Epidemiol, 2015, 7:201-212. 被引量:1
  • 5SmithJG, LukK, SchulzCA, et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis[J]. JAMA, 2014, 312(17):1764-1771. 被引量:1
  • 6CannonCP, BlazingMA, GiuglianoRP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes[J]. N Engl J Med, 2015, 372(25):2387-2397. 被引量:1
  • 7Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)[J]. Lancet, 1994, 344(8934):1383-1389. 被引量:1
  • 8SacksFM, PfefferMA, MoyeLA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators[J]. N Engl J Med, 1996, 335(14):1001-1009. 被引量:1
  • 9Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group[J]. N Engl J Med, 1998, 339(19):1349-1357. 被引量:1
  • 10血脂康调整血脂对冠心病二级预防研究协作组.中国冠心病二级预防研究[J].中华心血管病杂志,2005,33(2):109-115. 被引量:221

二级参考文献27

  • 1李莹,王抒,陈文祥,徐晨,吕敏,李健斋.多中心临床试验研究中血脂测定室间质量控制[J].中华检验医学杂志,2004,27(10):656-659. 被引量:5
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5224
  • 3中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南.中华心血管病杂志,2001,29:315-317. 被引量:7
  • 4Stone NJ,Robinson J,Lichtenstein AH,et al.2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J].Circulation,2013,pii:S0735-1097 (13)06028-2. 被引量:1
  • 5Scandinavian simvastatin survival study group.Randomised trial of lowering in 4444 patients with coronary heart disease:the Scandinavian simvastatin survival study (4S)[J].Lancet,1994,344:1383-1389. 被引量:1
  • 6Sharp collaborative group.Study of heart and renal protection (SHARP):randomized trial to assess the effects of lowering lowdensity lipoprotein cholesterol among 9438 patients with chronic kidney disease[J].Am Heart J,2010,160:785-794.e10. 被引量:1
  • 7Baigent C,Blackwell L,Emberson J,et al.Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170000 participants in 26 randomised trials[J].Lancet,2010,376:1670-1681. 被引量:1
  • 8FDA Drug Safety Communication:New restrictions,contraindications,and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury[EB/OL].(2011-06-08)[2014-03-27].http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. 被引量:1
  • 9The National Lipid Association recommendations for patientcentered treatment of dyslipidemia[EB/OL].(2014-05-20)[2014-05-21].https://www.lipid.org/nla/recommendationspatient-centered-management-dyslipidemia. 被引量:1
  • 10Cannon CP,Braunwald E,McCabe CH,et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].N Engl J Med,2004,350:1495-1504. 被引量:1

共引文献477

同被引文献65

引证文献7

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部